These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8167013)

  • 41. Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin.
    Tenover FC; Baker CN
    J Antimicrob Chemother; 1997 May; 39 Suppl A():81-5. PubMed ID: 9511069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changing susceptibilities of coagulase-negative staphylococci to teicoplanin in a teaching hospital.
    Sloos JH; van de Klundert JA; Dijkshoorn L; van Boven CP
    J Antimicrob Chemother; 1998 Dec; 42(6):787-91. PubMed ID: 10052903
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Drug resistance of 100 clinical strains of Enterococcus spp].
    Sawicka-Grzelak A; Rokosz A; Luczak M
    Med Dosw Mikrobiol; 1999; 51(3-4):239-47. PubMed ID: 10803253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
    Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Study to assess the reliability of a disc diffusion method for determining the sensitivity of gram-positive pathogens to dalfopristin/quinupristin.
    Andrews JM; Ashby JP; Wise R
    J Antimicrob Chemother; 1999 Jan; 43(1):141-3. PubMed ID: 10381113
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides.
    Del' Alamo L; Cereda RF; Tosin I; Miranda EA; Sader HS
    Diagn Microbiol Infect Dis; 1999 Jul; 34(3):185-91. PubMed ID: 10403098
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A study on the disc sensitivity test for cefsulodin].
    Kanazawa Y; Kuramata T; Matsumoto K
    Jpn J Antibiot; 1983 Jan; 36(1):103-10. PubMed ID: 6842821
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Heterogeneity of Brain Heart Infusion agar media (BHI): effects on the determination of the vancomycin and the teicoplanin minimal inhibitory concentrations (MIC) of Staphylococcus aureus strains].
    Martin C
    Pathol Biol (Paris); 2004 Oct; 52(8):450-4. PubMed ID: 15465263
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin.
    O'Connor R; Baines SD; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2008 Oct; 62(4):762-5. PubMed ID: 18606787
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A study on the disc sensitivity test for cefmenoxime].
    Kanazawa Y; Kuramata T; Matsumoto K
    Jpn J Antibiot; 1984 Jan; 37(1):176-83. PubMed ID: 6328060
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan.
    Kobayashi Y
    J Infect Chemother; 2005 Oct; 11(5):259-61. PubMed ID: 16258825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical laboratory approach in estimating effective administrative dose of piperacillin. Reevaluation of MIC break points in 3 and 4 category systems of disc susceptibility test].
    Matsuo K; Uete T
    Jpn J Antibiot; 1990 Sep; 43(9):1559-71. PubMed ID: 2262963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs.
    Vedel G; Leruez M; Lémann F; Hraoui E; Ratovohery D
    Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):820-2. PubMed ID: 2150815
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of medium composition on bacterial susceptibility testing to gentamicin and netilmicin.
    Dornbusch K
    Scand J Infect Dis Suppl; 1980; Suppl 23():46-53. PubMed ID: 6937968
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A study of the disc sensitivity test for cephradine].
    Kanazawa Y; Kuramata T; Matsumoto K
    Jpn J Antibiot; 1982 Jul; 35(7):1722-9. PubMed ID: 7176072
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of vancomycin and teicoplanin against anaerobic bacteria.
    Robbins MJ; Marais R; Felmingham D; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1987; 13(9):551-4. PubMed ID: 2962846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of in vitro activity of teicoplanin against recent clinical isolates.
    Nani E; Amato G; Anzivino D; Covelli B; Lembo M
    Chemioterapia; 1988 Feb; 7(1):20-3. PubMed ID: 2967737
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Susceptibility of Brazilian staphylococcal strains to glycopeptides evaluated by different testing methods.
    Ferreira Nunes AP; Martins Teixeira L; Reis Bastos CC; de Souza Fonseca L; Netto dos Santos KR
    Curr Microbiol; 2002 Jun; 44(6):385-90. PubMed ID: 12000986
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Evaluation of the disc sensitivity test for cefmetazole].
    Kanazawa Y; Kuramata T; Matsumoto K
    Jpn J Antibiot; 1983 Aug; 36(8):2065-72. PubMed ID: 6581340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.